Pharma BD Deal Intelligence
Pfizer's $14B cash deal for XTANDI cemented enzalutamide as a core Pfizer oncology franchise and added talazoparib to the pipeline—a clean bolt-on that delivered exactly what it promised, no integration drama required.
Pfizer buying Medivation in deal valued at about $14 billion.
Pfizer and its acquisition subsidiary filed a Tender Offer Statement on Schedule TO and Medivation filed a Solicitation/Recommendation Statement on Schedule…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Pfizer acquired Medivation for approximately $14 billion ($81.50 per share in cash), gaining full ownership of XTANDI (enzalutamide) for prostate cancer and the Phase III PARP inhibitor talazoparib, strengthening Pfizer's oncology portfolio.
161K US cases/yr · $10.0B Global Prostate Cancer Market (2016) · $4.2B XTANDI Peak Revenue (2022)
Prostate cancer is the most common cancer in US men. XTANDI (enzalutamide) is a next-gen androgen receptor inhibitor co-developed with Astellas, becoming standard of care across CRPC settings.
XTANDI competed with Zytiga (abiraterone) and later darolutamide (Nubeqa). Label expansions into earlier settings drove growth. Pfizer gained US commercialization rights.
Pfizer announces $14B acquisition of Medivation to accelerate oncology leadership with Xtandi.
Pfizer acquires Medivation at $81.50/share, gaining full ownership of Xtandi for prostate cancer.
At close, Xtandi generating ~$2.2B worldwide. Pfizer expects immediate revenue growth acceleration.
Xtandi gains additional prostate cancer indications (nmCRPC, mCSPC), expanding addressable market.
Xtandi becomes top oncology franchise globally with Pfizer/Astellas combined sales exceeding $4B.
Xtandi revenues roughly doubled post-acquisition via label expansions. Established Pfizer as oncology player.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Medivation Inc. (this deal) | 2016 | $14.0B | 86 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
| Pfizer Inc. / Seagen Inc. | 2023 | $43.0B | 77 |
← Browse all deals · How we score deals
More: 2016 deals · Pfizer Inc. deals · Oncology deals